Increased cyclosporin A sensitivity in vivo in pediatric renal transplant recipients compared with adults

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 554-560

  Billing, Heiko ^a   Sommerer, Claudia ^a   Giese, Thomas ^b   Zeier, Martin ^a   Meuer, Stefan ^b   Czock, David ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

cyclosporin A; developmental pharmacodynamics; interferon ; interleukin 2; renal transplantation; therapeutic drug monitoring

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; FEMALE; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CYCLOSPORINE; FEMALE; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84866544702     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182697655     Document Type: Article

References (18)

1. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157-1167.
2. Mulla H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr Drugs. 2010;12:223-233.
3. Takahashi H, Ishikawa S, Nomoto S, et al. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther. 2000;68:541-555.
4. Marshall J, Rodarte A, Blumer J, et al. Pediatric pharmacodynamics of midazolam oral syrup. J Clin Pharmacol. 2000;40:578-589.
5. de Wildt SN, Kearns GL, Sie HD, et al. Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin Drug Invest. 2003;23:27-38.
6. Lin CS, Boltz RC, Siekierka JJ, et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol. 1991;133:269-284.
7. Sehajpal PK, Sharma VK, Ingulli E, et al. Synergism between the CD3 antigen-and CD2 antigen derived signals: exploration at the level of induction of DNA-binding proteins and characterization of the inhibitory activity of cyclosporine. Transplantation. 1993;55:1118-1124.
8. Hayward AR. Development of lymphocyte responses and interactions in the human fetus and newborn. Immunol Rev. 1981;57:39-60.
9. Härtel C, Adam N, Strunk T, et al. Cytokine responses correlate differentially with age in infancy and early childhood. Clin Exp Immunol. 2005;142:446-453.
10. McDouall RM, Suitters AJ, Smith H, et al. Increased cyclosporine sensitivity of T cells from cord blood compared with those from the adult. Clin Exp Immunol. 1994;95:519-524.
11. Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther. 1999;66:66-75.
12. Giese T, Zeier M, Meuer S. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant. 2004;19: iv55-iv60.
13. Quien RM, Kaiser BA, Dunn SP, et al. Calcineurin activity in children with renal transplants receiving cyclosporine. Transplantation. 1997;64:1486-1489.
14. Giese T, Zeier M, Schemmer P, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004;77:339-344.
15. Tsao PW, Diaz RJ, Radde IC, et al. Age-related differences in the effects of cyclosporine in lymphocyte intracellular free calcium. Transplantation. 1991;52:345-349.
16. Weber LT, Armstrong VW, Shipkova M, et al. Members of the German Study Group on Pediatric Renal Transplantation. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. Ther Drug Monit. 2004;26:415-424.
17. Einecke G, Mai I, Fritsche L, et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant. 2004;19:215-222.
18. Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclospor-ine A in elderly (.65 years) kidney transplant recipients. Transplantation. 2008;86:1379-1383.